<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0194330</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-23206</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Chronic kidney disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject><subj-group><subject>Creatinine</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical medicine</subject><subj-group><subject>Clinical trials</subject><subj-group><subject>Randomized controlled trials</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug research and development</subject><subj-group><subject>Clinical trials</subject><subj-group><subject>Randomized controlled trials</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Clinical trials</subject><subj-group><subject>Randomized controlled trials</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Science policy</subject><subj-group><subject>Research integrity</subject><subj-group><subject>Publication ethics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Renal system</subject><subj-group><subject>Kidneys</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials</article-title>
<alt-title alt-title-type="running-head">CIN between iodixanol and LOCM in diabetic patients</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Han</surname>
<given-names>Xiao-fang</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Xin-xiu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Ke-mei</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tan</surname>
<given-names>Hua</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhang</surname>
<given-names>Qiu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Endocrinology, The Second People's Hospital of Hefei, Anhui, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Center for Bioinformatics &amp; Systems Biology, Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Remuzzi</surname>
<given-names>Giuseppe</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Istituto Di Ricerche Farmacologiche Mario Negri, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">qiuzhang_ah@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<elocation-id>e0194330</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Han et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0194330"/>
<abstract>
<sec id="sec001">
<title>Purpose</title>
<p>This study was conducted to compare iso-osmolar contrast medium, iodixanol, with low-osmolar contrast media (LOCM) for assessing contrast-induced nephropathy (CIN) incidence, exclusively in the diabetic population.</p>
</sec>
<sec id="sec002">
<title>Method</title>
<p>A systematic search was conducted for full-text, prospective, randomized controlled trials (RCTs). The primary outcome was incidence of CIN. Medline, Cochrane Central Register of Controlled Trials, and other sources were searched until May 31, 2017.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Twelve RCTs finally met the search criteria. Iodixanol did not significantly reduce the risk of CIN (risk ratio [RR]: 0.72, 95% confidence interval (CI): [0.49, 1.04], p = 0.08). However, there was significantly reduced risk of CIN when iodixanol was compared to a LOCM agent iohexol (RR: 0.32, 95% CI [0.12, 0.89]). There were no differences between iodixanol and the other non-iohexol LOCM (RR: 0.92, 95% CI [0.68, 1.25]).</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>In diabetic populations, iodixanol is not associated with a significant reduction of CIN risk. Iodixanol is associated with a reduced risk of CIN compared with iohexol, whereas no significant difference between iodixanol and other LOCM could be found.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>NSFC</institution>
</funding-source>
<award-id>81602468</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhang</surname>
<given-names>Qiu</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by Anhui Provincial Natural Science Foundation, 1608085MH208.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Contrast-induced nephropathy (CIN), is an acute impairment in renal function, and typically occurs within 3 days following the exposure of a contrast medium (CM) [<xref ref-type="bibr" rid="pone.0194330.ref001">1</xref>–<xref ref-type="bibr" rid="pone.0194330.ref003">3</xref>]. In the United States, CIN is one of the leading causes of acute kidney injury, accounting for 11–14.5% [<xref ref-type="bibr" rid="pone.0194330.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0194330.ref005">5</xref>], and is associated with increased cost, hospital stay, and long-term morbidity and mortality [<xref ref-type="bibr" rid="pone.0194330.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0194330.ref008">8</xref>].</p>
<p>Patients at highest risk for CIN include these with pre-existing renal injury, particularly when it is secondary to diabetic nephropathy (DN). It has been recognized that adults with diabetes have a higher risk of developing DN than those without this disease [<xref ref-type="bibr" rid="pone.0194330.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0194330.ref010">10</xref>]. A milestone meta-analysis [<xref ref-type="bibr" rid="pone.0194330.ref011">11</xref>] mentioned the independent predictors of CIN included chronic kidney disease (CKD), CKD with DM, and use of LOCM. However, CKD with DM group had a much higher increase of maximum serum creatinine (SCr), than CKD without DM after contrast exposure. Also, paramount to say that this meta [<xref ref-type="bibr" rid="pone.0194330.ref011">11</xref>] extracted more data from internal database of GE Healthcare, the manufacturer of iso-osmolar contrast media iodixanol. Besides, some evidences investigated the diabetic patients may have some degree of reduced renal function despite having normal SCr levels [<xref ref-type="bibr" rid="pone.0194330.ref012">12</xref>–<xref ref-type="bibr" rid="pone.0194330.ref014">14</xref>]. And, a pilot small RCT [<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>] proved that in diabetic patients, iodixanol was associated with a lower incidence of CIN than low-osmolar ioversol. So far, it has no systemic reviews or meta-analyses to compare iodixanol with LOCM, exclusively in the diabetic population <italic>per se</italic> with or without renal insufficiency.</p>
<p>This meta-analysis will expand prior analyses by incorporating all fully-published, prospective RCTs. More specifically, our study will focus on the diabetic population with or without CKD to provide a comparison for nephrotoxicity between the iso-osmolar agent iodixanol and the LOCM.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Data sources and search strategy</title>
<p>A computerized search to identify eligible RCTs was conducted using the databases of Medline (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL, 1999–2017 John Wiley &amp; Sons, Inc.), the internal database of GE Healthcare, the manuscript of iodixanol as well as references of retrieved articles and prior meta-analyses, using the following keywords: “Contrast-induced nephropathy,” “contrast-induced acute kidney injury,” “contrast medium,” “iodixanol,” “visipaque,” “iso-osmolar,” “low-osmolar,” “nephropathy,” “nephrotoxicity” and “renal dysfunction”.</p>
</sec>
<sec id="sec008">
<title>Study selection</title>
<p>RCTs were included of comparing CIN events in diabetic patients who were given iso-osmolar iodixanol versus LOCM. Studies were eligible for inclusion if they prospectively randomized patients to either iodixanol or at least one kind of LOCM, and if data on renal function or CIN was routinely ascertained. The primary outcome was the incidence of CIN, defined as an absolute increase at least 0.5 mg/dL (44.2 μmol/L) or relative increase at least 25% from baseline value of SCr, based on current recommendations by the European Society of Urogenital Radiology (ESUR) in the year of 1999 [<xref ref-type="bibr" rid="pone.0194330.ref001">1</xref>] and 2011[<xref ref-type="bibr" rid="pone.0194330.ref002">2</xref>] as well as the Canadian Association of Radiologists [<xref ref-type="bibr" rid="pone.0194330.ref003">3</xref>]. Only fully-published, prospective, RCTs were included for quantitative assessment. Studies that were retrospective, non-randomized or those in which patients were not randomized to either iodixanol or LOCM were excluded strictly. Exclusion also applied to those without available data regarding the patients with diabetes mellitus. No restrictions were placed on languages or sample sizes.</p>
</sec>
<sec id="sec009">
<title>Quality assessment</title>
<p>We used the Cochrane Collaboration’s recommended tool for assessing the risk of bias in included studies [<xref ref-type="bibr" rid="pone.0194330.ref016">16</xref>]. To determine an overall quality of included studies, we assessed trial’s quality by evaluating every element of study design (i.e., blinding description, randomization process, inclusion and exclusion criteria, concealed allocation, intention-to-treat analysis, and assessment of withdrawals and dropouts), together with Jadad scoring system. Risk for bias was assessed in duplicate, with disagreements resolved by consensus. Potential publication bias was further assessed by Begg’s funnel plot [<xref ref-type="bibr" rid="pone.0194330.ref017">17</xref>].</p>
</sec>
<sec id="sec010">
<title>Data extraction</title>
<p>Data were independently extracted by two reviewers (HX, ZX), and disagreements were resolved by consensus with the third reviewer (LK). The primary outcome, incidence of CIN, was extracted. Baseline demographic, clinical, and procedural characteristics were recorded, including patients’ characteristics (i.e. age), sample sizes, type of LOCM (i.e. iohexol, <xref ref-type="supplementary-material" rid="pone.0194330.s001">S1 Table</xref>), iodine concentration (i.e. iohexol 300 mg I/mL) and time frame of CIN after exposure of contrast was also extracted.</p>
</sec>
<sec id="sec011">
<title>Data analysis</title>
<p>Analyses were mainly performed with Review Manager Software (RevMan Analyses Version 5.3.Copenhagen; The Nordic Cochrane Center, The Cochrane Collaboration, 2014). For dichotomous variables, the risk ratio (RR) was measured along with a 95% confidence interval (CI). A 95% CI not including 1 or p&lt;0.05 was considered to be statistically significant. The inter-study statistical heterogeneity was examined by both Chi-squared tests and I<sup>2</sup> statistics. A random-effects model was performed to attain a more relative conservative result. To explore sources of heterogeneity, each study was removed one by one to detect its contribution. If removal of the studies using this process did not create a statistical significant change, the results would be considered robust. Potential publication bias and skewness were assessed graphically using funnel plots in RevMan, if the included studies were greater than or equal to 10.</p>
<p>Subgroup analyses were also conducted based on the formulations of LOCM, which were also divided as iohexol group and non-iohexol group. All CIN events were incorporated, in spite of variant definitions of CIN. Thus, 4 studies [<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>] supplied available data of both two CIN definitions. In this study, we named, i.e. <italic>Chen (1) 2012</italic> that meant Chen 2012 [<xref ref-type="bibr" rid="pone.0194330.ref019">19</xref>] with the data of relative CIN criterion, while the <italic>Chen (2) 2012</italic> meant the absolute criterion.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Study selection</title>
<p>Medline (via PubMed), CENTRAL (search criterion in <xref ref-type="supplementary-material" rid="pone.0194330.s002">S2 Table</xref>) and other sources were searched from inception to May 31, 2017.</p>
<p>A total of 1367 potentially relevant studies were identified. Of these, 398 were duplicates and 474 had no association or available data about CIN based on review of title and abstract. Of the 103 remaining studies for full-text assessment, 61 didn’t compare iodixanol with LOCM and the other 30 were excluded as they had no available data individually about diabetic populations. Finally, 12 prospective full-text trials [<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0194330.ref028">28</xref>] were included in the process of qualitative analysis (<xref ref-type="fig" rid="pone.0194330.g001">Fig 1</xref>). Demographic and baseline characteristics of the 12 trials were summarized (<xref ref-type="table" rid="pone.0194330.t001">Table 1</xref>). Elements of study quality were listed as blinding description, randomization process, inclusion and exclusion criteria, concealed allocation, intention-to-treat analysis and assessment of withdrawals and dropouts. And the total quality was assessed by Jadad scores (<xref ref-type="supplementary-material" rid="pone.0194330.s003">S3 Table</xref>). Among these studies, all were prospective, double-blind RCTs with a score greater than 3 scores, other than Hernandez 2009[<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>], a single-center, open-label but prospective, randomized study. The study was also consistent with the protocol of PRISMA [<xref ref-type="bibr" rid="pone.0194330.ref029">29</xref>] (<bold>P</bold>referred <bold>R</bold>eporting <bold>I</bold>tems for <bold>S</bold>ystematic reviews and <bold>M</bold>eta-<bold>A</bold>nalyses statement, <xref ref-type="supplementary-material" rid="pone.0194330.s004">S4 Table</xref>).</p>
<fig id="pone.0194330.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0194330.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of selection strategy.</title>
<p>Flow diagram depicting the selection strategy for trials used in this meta-analysis. 12 RCTs finally met our criteria. RCT = randomized clinical trials.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0194330.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0194330.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of trials.</title></caption>
<alternatives>
<graphic id="pone.0194330.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify" rowspan="2">First Author</th>
<th align="justify" rowspan="2">publish Year</th>
<th align="justify" rowspan="2">Acronym</th>
<th align="left" rowspan="2">Patients’ charecteristic</th>
<th align="justify" rowspan="2">Primary outcome<xref ref-type="table-fn" rid="t001fn001">*</xref></th>
<th align="justify" rowspan="2">LOCM<xref ref-type="table-fn" rid="t001fn002"><sup>†</sup></xref></th>
<th align="center" colspan="3">Patients, n</th>
<th align="center" colspan="2">Mean age<xref ref-type="table-fn" rid="t001fn003">‡</xref></th>
<th align="center" colspan="2">Male, (%)</th>
<th align="center" colspan="2">DM, (%)</th>
</tr>
<tr>
<th align="justify">Total</th>
<th align="justify">Iodixanol</th>
<th align="justify">LOCM</th>
<th align="justify">Iodixanol</th>
<th align="justify">LOCM</th>
<th align="justify">Iodixanol</th>
<th align="justify">LOCM</th>
<th align="justify">Iodixanol</th>
<th align="justify">LOCM</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify">Aspelin</td>
<td align="justify">2003</td>
<td align="justify">NEPHRIC</td>
<td align="justify">DM and CKD</td>
<td align="justify">peak increase of SCr between day 0 and 3</td>
<td align="justify">iohexol, 350</td>
<td align="justify">129</td>
<td align="justify">64</td>
<td align="justify">65</td>
<td align="justify">71.1±6.0</td>
<td align="justify">70.6±8.6</td>
<td align="justify">64</td>
<td align="justify">53.8</td>
<td align="justify">100</td>
<td align="justify">100</td>
</tr>
<tr>
<td align="justify">Jo</td>
<td align="justify">2006</td>
<td align="justify">RECOVER</td>
<td align="justify">CKD</td>
<td align="justify">SCr≥0.5 or ≥25% on day 1–2</td>
<td align="justify">ioxaglate, NR</td>
<td align="justify">275</td>
<td align="justify">140</td>
<td align="justify">135</td>
<td align="justify">66.1±8.6</td>
<td align="justify">68.7±7.5</td>
<td align="justify">56.4</td>
<td align="justify">55.6</td>
<td align="justify">34.3</td>
<td align="justify">36.3</td>
</tr>
<tr>
<td align="justify">Feldkamp</td>
<td align="justify">2006</td>
<td align="justify">NR</td>
<td align="justify">normal renal function</td>
<td align="justify">SCr≥25% or CrCl &lt;20%</td>
<td align="justify">iopromide, 300</td>
<td align="justify">221</td>
<td align="justify">105</td>
<td align="justify">116</td>
<td align="justify">60.6±10.0</td>
<td align="justify">62.1 ± 9.2</td>
<td align="justify">75.2</td>
<td align="justify">75.9</td>
<td align="justify">21.9</td>
<td align="justify">20.7</td>
</tr>
<tr>
<td align="justify">Solomon</td>
<td align="justify">2007</td>
<td align="justify">CARE</td>
<td align="justify">CKD</td>
<td align="justify">SCr≥0.5 in 45–120 hrs</td>
<td align="justify">iopamidol, 370</td>
<td align="justify">414</td>
<td align="justify">210</td>
<td align="justify">204</td>
<td align="justify">70.5±9.9</td>
<td align="justify">72.4±9.0</td>
<td align="justify">60.5</td>
<td align="justify">67.6</td>
<td align="justify">43.8</td>
<td align="justify">38.2</td>
</tr>
<tr>
<td align="justify">Rudnick</td>
<td align="justify">2008</td>
<td align="justify">VALOR</td>
<td align="justify">CKD</td>
<td align="justify">SCr&gt;0.5 within 3d</td>
<td align="justify">ioversol, 320</td>
<td align="justify">299</td>
<td align="justify">156</td>
<td align="justify">143</td>
<td align="justify">71.1 ± 9.9</td>
<td align="justify">72.6 ± 10.2</td>
<td align="justify">68</td>
<td align="justify">74</td>
<td align="justify">52</td>
<td align="justify">52</td>
</tr>
<tr>
<td align="justify">Hardiek</td>
<td align="justify">2008</td>
<td align="justify">NR</td>
<td align="justify">DM and CKD</td>
<td align="justify">SCr≥25%</td>
<td align="justify">iopamidol, 370</td>
<td align="justify">102</td>
<td align="justify">54</td>
<td align="justify">48</td>
<td align="justify">65±10</td>
<td align="justify">66±10</td>
<td align="justify">48</td>
<td align="justify">67</td>
<td align="justify">100</td>
<td align="justify">100</td>
</tr>
<tr>
<td align="justify">Kuhn</td>
<td align="justify">2008</td>
<td align="justify">PREDICT</td>
<td align="justify">DM and CKD</td>
<td align="justify">SCr≥25% on day 2–3</td>
<td align="justify">iopamidol, 370</td>
<td align="justify">248</td>
<td align="justify">123</td>
<td align="justify">125</td>
<td align="justify">68.3 ± 9.19</td>
<td align="justify">69.5 ±10.05</td>
<td align="justify">43.2</td>
<td align="justify">50.4</td>
<td align="justify">100</td>
<td align="justify">100</td>
</tr>
<tr>
<td align="justify">Hernández</td>
<td align="justify">2009</td>
<td align="justify">NR</td>
<td align="justify">DM</td>
<td align="justify">SCr≥0.5 or 25% on day 3</td>
<td align="justify">ioversol, 350</td>
<td align="justify">250</td>
<td align="justify">118</td>
<td align="justify">132</td>
<td align="justify">69.1±9.0</td>
<td align="justify">70.1±7.9</td>
<td align="justify">61.9</td>
<td align="justify">64.4</td>
<td align="justify">100</td>
<td align="justify">100</td>
</tr>
<tr>
<td align="justify">Laskey</td>
<td align="justify">2009</td>
<td align="justify">NR</td>
<td align="justify">CKD, DM</td>
<td align="justify">SCr≥0.5 within 3d</td>
<td align="justify">iopamidol, 370</td>
<td align="justify">526</td>
<td align="justify">263</td>
<td align="justify">263</td>
<td align="justify">69.5±8.7</td>
<td align="justify">69.8±8.9</td>
<td align="justify">67</td>
<td align="justify">66</td>
<td align="justify">100</td>
<td align="justify">100</td>
</tr>
<tr>
<td align="justify">Chuang</td>
<td align="justify">2009</td>
<td align="justify">NR</td>
<td align="justify">CKD with or with DM</td>
<td align="justify">SCr≥25% with 7 days</td>
<td align="justify">Iohexol, NR</td>
<td align="justify">50</td>
<td align="justify">25</td>
<td align="justify">25</td>
<td align="justify">62.9 ± 13.7</td>
<td align="justify">53.0 ± 12.2</td>
<td align="justify">72</td>
<td align="justify">64</td>
<td align="justify">40</td>
<td align="justify">36</td>
</tr>
<tr>
<td align="justify">Shin</td>
<td align="justify">2011</td>
<td align="justify">NR</td>
<td align="justify">CKD</td>
<td align="justify">SCr≥0.5 or 25% after the procedure</td>
<td align="justify">iopromide, 300</td>
<td align="justify">420</td>
<td align="justify">215</td>
<td align="justify">205</td>
<td align="justify">71.1±8.7</td>
<td align="justify">71.9±8.2</td>
<td align="justify">57</td>
<td align="justify">51</td>
<td align="justify">44</td>
<td align="justify">49</td>
</tr>
<tr>
<td align="justify">Chen</td>
<td align="justify">2012</td>
<td align="justify">DIRECT</td>
<td align="justify">CKD</td>
<td align="justify">SCr≥50% on day 3</td>
<td align="justify">iopromide, 370</td>
<td align="justify">562</td>
<td align="justify">284</td>
<td align="justify">278</td>
<td align="justify">70.0±9.25</td>
<td align="justify">69.0±10.5</td>
<td align="justify">66.9</td>
<td align="justify">67.6</td>
<td align="justify">32.7</td>
<td align="justify">27.7</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>*: mg/dL is used to calculate SCr; mL/min to CrCl</p></fn>
<fn id="t001fn002"><p>†: mg I/ml to LOCM</p></fn>
<fn id="t001fn003"><p>‡: Values reported as mean±SD</p></fn>
<fn id="t001fn004"><p>LOCM = low-osmolar contrast media; DM = diabetes mellitus; CKD = chronic kidney disease; SCr = serum creatinine; CrCl = creatinine clearance; NR = nor reported.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Data extraction</title>
<p>In the included studies, the incidence of CIN was reported. Among all studies, only five [<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>,<xref ref-type="bibr" rid="pone.0194330.ref020">20</xref>,<xref ref-type="bibr" rid="pone.0194330.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0194330.ref028">28</xref>] recruited the diabetic populations. As for the remaining 7 studies [<xref ref-type="bibr" rid="pone.0194330.ref019">19</xref>,<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0194330.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0194330.ref024">24</xref>–<xref ref-type="bibr" rid="pone.0194330.ref027">27</xref>], the available data of CIN in the diabetic patients were listed as a subgroup and disclosed in the main text. All data were extracted from the published articles directly.</p>
</sec>
<sec id="sec015">
<title>CIN definition</title>
<p>The primary outcome of our study was the incidence of CIN, defined as a relative increase in the SCr of at least 25% or an absolute increase of at least 0.5 mg/dl from the baseline value after contrast medium exposure. Among all studies, 4 trials [<xref ref-type="bibr" rid="pone.0194330.ref020">20</xref>,<xref ref-type="bibr" rid="pone.0194330.ref026">26</xref>–<xref ref-type="bibr" rid="pone.0194330.ref028">28</xref>] defined CIN as SCr ≥25% as the primary clinical endpoint, 3 defines as SCr ≥0.5 mg/dl [<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0194330.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0194330.ref024">24</xref>], and another 3 either [<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0194330.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0194330.ref025">25</xref>]. Besides, 4 studies [<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>] also supplied other available data of CIN other than the primary outcome defined individually in each study.</p>
</sec>
<sec id="sec016">
<title>Relative criterion of CIN</title>
<p>Available data from 7 studies [<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0194330.ref026">26</xref>–<xref ref-type="bibr" rid="pone.0194330.ref028">28</xref>] disclosed the incidence of CIN after contrast media exposure, which was defined as a relative increase in the SCr of at least 25% from the baseline.</p>
<p>In total, CIN occurred among 45 out of 493 who received iodixanol, and 58 of 459 patients who received LOCM (n = 952, RR: 0.72, 95% confidence interval [CI]: 0.49–1.04, p = 0.08, I<sup>2</sup> = 0%, <xref ref-type="fig" rid="pone.0194330.g002">Fig 2</xref>), indicating that there was slight reduction of incident CIN associated with iodixanol in comparison to LOCM, but insignificantly.</p>
<fig id="pone.0194330.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0194330.g002</object-id>
<label>Fig 2</label>
<caption>
<title>RR of CIN for comparison of iodixanol with LOCM in diabetic patients.</title>
<p>Forest plot of risk ratios (RR) for the incidence of contrast-induced nephropathy (CIN) for comparison of iodixanol with low-osmolar contrast media (LOCM). CIN was defined as an increase of more than 25%, or 0.5 mg/dL (44.2 μmol/L), or either, in serum creatinine level (SCr), respectively. LOCM low-osmolar contrast medium/media; CI confidence interval; M-H Mantel-Haenszel method.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.g002" xlink:type="simple"/>
</fig>
<p>However, the nonsignificant result wasn’t robust after removing the study of Solomon 2007[<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>] (RR: 0.59, 95% CI: 0.59–0.90, p = 0.01, I<sup>2</sup> = 0%).</p>
</sec>
<sec id="sec017">
<title>Absolute criterion of CIN</title>
<p>Separately, available data from 6 studies [<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0194330.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0194330.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0194330.ref024">24</xref>] uncovered the incident CIN defined as an absolute increase in the SCr of at least 0.5 mg/dl after given contrast media.</p>
<p>Totally, the events of CIN occurred among 55 out of 575 who received iodixanol, and 61 of 525 patients who received LOCM (n = 1100, RR: 0.72, 95% CI: 0.33–1.59, p = 0.42, <xref ref-type="fig" rid="pone.0194330.g002">Fig 2</xref>), indicating that there was no significant difference of incident CIN associated with iodixanol in comparison to LOCM, with a higher heterogeneity (p = 0.009, I<sup>2</sup> = 67%).</p>
<p>Furthermore, the results were robust after removing each study one by one to detect its contribution without a statistically significant change.</p>
</sec>
<sec id="sec018">
<title>Relative or absolute definition of CIN</title>
<p>Only 3 studies [<xref ref-type="bibr" rid="pone.0194330.ref015">15</xref>,<xref ref-type="bibr" rid="pone.0194330.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0194330.ref025">25</xref>] defined the CIN as SCr≥25% or ≥0.5 mg/dl, without other available data separately. In total, CIN occurred among 20 out of 260 who received iodixanol, and 33 of 281 patients who received LOCM (RR: 0.59, 95% CI: 0.22–1.60, p = 0.30, <xref ref-type="fig" rid="pone.0194330.g002">Fig 2</xref>), indicating that there was no significant reduction of CIN rate associated with iodixanol in comparison to LOCM.</p>
</sec>
<sec id="sec019">
<title>Iodixanol versus LOCM</title>
<p>Subgroup analyses were conducted based on the formulations of contrast media (<xref ref-type="fig" rid="pone.0194330.g003">Fig 3</xref>). Patients receiving nonionic, monomeric LOCM were given iohexol (3 trials), iopamidol (7 trials), iopromide (4 trials), ioversol (2 trial), as well as ionic dimer, ioxaglate (1 trial).</p>
<fig id="pone.0194330.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0194330.g003</object-id>
<label>Fig 3</label>
<caption>
<title>RR of CIN for comparison of iodixanol with iohexol or other non-iohexol LOCM.</title>
<p>Funnel plot of studies for contrast-induced nephropathy (CIN) for comparison of iodixanol with iohexol or other non-iohexol LOCM in diabetic patients.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.g003" xlink:type="simple"/>
</fig>
<p>There was a significant reduction of CIN when iodixanol was compared to iohexol (n = 308, RR: 0.32, 95% CI: 0.12 to 0.89, p = 0.03; I<sup>2</sup> = 40%), iopromide (n = 617, RR: 0.95, 95% CI: 0.53 to 1.70, p = 0.86) and iopamidol (n = 1,311, RR: 0.96, 95% CI: 0.58 to 1.60, p = 0.88). However, there was no significant difference between iodixanol and iopromide (n = 617, RR: 0.95, 95% CI: 0.53 to 1.70, p = 0.86) and iopamidol (n = 1,311, RR: 0.96, 95% CI: 0.58 to 1.60, p = 0.88). Furthermore, when iodixanol was compared to non-iohexol LOCMs, there was also no significant (n = 2,375, RR: 0.92, 95% CI: 0.68 to 1.25, p = 0.93).</p>
</sec>
</sec>
<sec id="sec020" sec-type="conclusions">
<title>Discussion</title>
<sec id="sec021">
<title>Major findings</title>
<p>From including 12 prospective full-text RCTs to compare iso-osmolar CM, iodixanol, with LOCM for assessing the incidence of CIN exclusively in the patients with diabetes mellitus, numerous findings were found as follows: 1) iodixanol isn’t superior to LOCM to reducing the risk of CIN; 2) If the CIN is defined as a relative increase in SCr of at least 25% from baseline, iodixanol showed slightly reduced CIN incidence non-significantly. However, the result seems not very robust; 3) iodixanol is superior to iohexol to reduce the risk of CIN; 5) No significant difference between iodixanol and other non-iohexol LOCMs could be found</p>
</sec>
<sec id="sec022">
<title>Definitions of CIN</title>
<p>CIN was first defined in 1999 by ESUR [<xref ref-type="bibr" rid="pone.0194330.ref001">1</xref>] as an absolute increase in SCr of at least 0.5 mg/dl or a relative increase of &gt;25% of baseline value. Although this definition was followed by some standard guidelines [<xref ref-type="bibr" rid="pone.0194330.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0194330.ref003">3</xref>], a series of derivative definitions were still widely used in recent years, i.e. both absolute and relative increase, absolute increase solely, relative increase solely. Moreover, the upper limitations of SCr increase were not mandatory, which also deteriorated the consistency of criterion for CIN. For example, Chen 2012 [<xref ref-type="bibr" rid="pone.0194330.ref019">19</xref>] defined CIN as SCr increase ≥50%. Variant definitions brought inconsistency, even in the meta-analyses of RCTs. McCullough [<xref ref-type="bibr" rid="pone.0194330.ref011">11</xref>] firstly defined the CIN as SCr increase ≥0.5 mg/dl and found the iodixanol was associated with a reduced of CIN. While, From et al. [<xref ref-type="bibr" rid="pone.0194330.ref030">30</xref>] found that iodixanol was not associated with less CIN.</p>
<p>For avoiding the inconsistency of variant definitions, uniform criteria were conducted in this study. Also, the more widely-used definitions of SCr increase ≥25% or 0.5 mg/dl were adopted.</p>
</sec>
<sec id="sec023">
<title>The incidence of CIN in diabetic populations</title>
<p>There is general agreement that CKD is the most significant risk factor for CIN and every multivariate analysis has shown that CKD is an independent risk factor for CIN [<xref ref-type="bibr" rid="pone.0194330.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0194330.ref031">31</xref>–<xref ref-type="bibr" rid="pone.0194330.ref035">35</xref>]. A recently published meta-analysis reported a very closely related study, albeit examining chronic kidney disease patients rather than diabetic patients. Randomized trials comparing IOCM to LOCM in CKD stage 3 and above patients undergoing CA, and reporting incidence of CIN (defined by a rise in creatinine of 25% from baseline) were included in the analysis. In patients with CKD stage 3 and above undergoing coronary angiography, use of IOCM showed overall non-significant difference in incidence of CIN compared to LOCM. The difference was further attenuated when IOCM was compared with non-ionic LOCM [<xref ref-type="bibr" rid="pone.0194330.ref033">33</xref>]. Additionally, whether DM could be another independent risk factor for CIN is controversial. There is no conclusive evidence that diabetic patients weren’t at an increased risk of CIN if their renal function is normal [<xref ref-type="bibr" rid="pone.0194330.ref002">2</xref>]. The finding of this study indicated that iodixanol was not associated with a reduced risk of CIN, was based on the uniform definitions of CIN respectively, which indicated that DM <italic>per se</italic> wasn’t independent predictors of CIN.</p>
</sec>
<sec id="sec024">
<title>Iodixanol versus LOCM</title>
<p>Three prior meta-analyses, Reed 2009[<xref ref-type="bibr" rid="pone.0194330.ref036">36</xref>], Heinrich 2009[<xref ref-type="bibr" rid="pone.0194330.ref037">37</xref>] and From 2010[<xref ref-type="bibr" rid="pone.0194330.ref038">38</xref>] also found that iodixanol was associated with a reduction in CIN compared to iohexol, although significant differences between iodixanol and non-iohexol nonionic LOCM were inconsistent. Reed [<xref ref-type="bibr" rid="pone.0194330.ref036">36</xref>] reported that iodixanol was superior to ioxaglate. However, Heinrich [<xref ref-type="bibr" rid="pone.0194330.ref037">37</xref>] and From [<xref ref-type="bibr" rid="pone.0194330.ref038">38</xref>] indicated that iodixanol was not associated with a reduction in CIN when compared to non-iohexol.</p>
<p>This study indicated that in patients with diabetes mellitus, iodixanol wasn’t associated with significant renal protection when compared to nonionic LOCM other than iohexol. This finding couldn’t be explained solely by osmolality [<xref ref-type="bibr" rid="pone.0194330.ref018">18</xref>,<xref ref-type="bibr" rid="pone.0194330.ref037">37</xref>,<xref ref-type="bibr" rid="pone.0194330.ref038">38</xref>], which are warranted for further exploration of other possible mechanisms.</p>
</sec>
<sec id="sec025">
<title>Study strengths and limitations</title>
<p>One limitation of our study is that the results are based on the comprehensive data of trials with heterogeneous RCTs. The included trials utilized different radiographic procedures, contrast loads, heterogeneous definitions of CIN, or different complications of diabetic patients (CKD or not). We have attempted to account for these differences using random-effects models to obtain more conservative results. A significant strength of our study is the inclusion of mainly relevant RCTs on CIN, divided by each definition. In addition, Begg’s funnel plot analysis results (<xref ref-type="fig" rid="pone.0194330.g004">Fig 4</xref>) showed negligible publication bias in our study under all three definitions of CIN, demonstrating that our conclusions are reliable.</p>
<fig id="pone.0194330.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0194330.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Funnel plot for the association between contrast use and CIN under different definitions of CIN.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.g004" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec026">
<title>Supporting information</title>
<supplementary-material id="pone.0194330.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Characteristics of different contrast media of our studies.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0194330.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Search criterion of Medline (via PubMed), from inception to May 31, 2017; search criterion of cochrane Central Register of controlled trials, from inception to May 31, 2017.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0194330.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.s003" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Quality assessment of trials.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0194330.s004" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0194330.s004" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>The study was also consistent with the protocol of PRISMA.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors gratefully acknowledged the assistance of Mrs. Chanjuan Hu, the product manager of GE Healthcare Core Imaging, for assistance in searching available studies.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>CIN</term>
<def><p>Contrast-induced nephropathy</p></def>
</def-item>
<def-item><term>CM</term>
<def><p>contrast medium/media</p></def>
</def-item>
<def-item><term>CI</term>
<def><p>confidence interval</p></def>
</def-item>
<def-item><term>CKD</term>
<def><p>chronic kidney disease</p></def>
</def-item>
<def-item><term>DM</term>
<def><p>diabetes mellitus</p></def>
</def-item>
<def-item><term>DN</term>
<def><p>diabetic nephropathy</p></def>
</def-item>
<def-item><term>ESUR</term>
<def><p>European Society of Urogenital Radiology</p></def>
</def-item>
<def-item><term>LOCM</term>
<def><p>low-osmolar contrast medium/media</p></def>
</def-item>
<def-item><term>PRISMA</term>
<def><p>Preferred Reporting Items for Systematic reviews and Meta-analyses statement</p></def>
</def-item>
<def-item><term>RCT</term>
<def><p>randomized controlled trials</p></def>
</def-item>
<def-item><term>RR</term>
<def><p>risk ratio</p></def>
</def-item>
<def-item><term>SCr</term>
<def><p>serum creatinine</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pone.0194330.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morcos</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Thomsen</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Webb</surname> <given-names>JA</given-names></name> (<year>1999</year>) <article-title>Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR)</article-title>. <source>Eur Radiol</source> <volume>9</volume>: <fpage>1602</fpage>–<lpage>1613</lpage>. <object-id pub-id-type="pmid">10525875</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stacul</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>van der Molen</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Reimer</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Webb</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Thomsen</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Morcos</surname> <given-names>SK</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines</article-title>. <source>Eur Radiol</source> <volume>21</volume>: <fpage>2527</fpage>–<lpage>2541</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00330-011-2225-0" xlink:type="simple">10.1007/s00330-011-2225-0</ext-link></comment> <object-id pub-id-type="pmid">21866433</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benko</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fraser-Hill</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Magner</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Capusten</surname> <given-names>B</given-names></name>. (<year>2007</year>) <article-title>Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy</article-title>. <source>Can Assoc Radiol J</source> <volume>58</volume>: <fpage>79</fpage>–<lpage>87</lpage>. <object-id pub-id-type="pmid">17521052</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McCullough</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Wolyn</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rocher</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Levin</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>O'Neill</surname> <given-names>WW</given-names></name> (<year>1997</year>) <article-title>Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality</article-title>. <source>Am J Med</source> <volume>103</volume>: <fpage>368</fpage>–<lpage>375</lpage>. <object-id pub-id-type="pmid">9375704</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nash</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hafeez</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hou</surname> <given-names>S</given-names></name> (<year>2002</year>) <article-title>Hospital-acquired renal insufficiency</article-title>. <source>Am J Kidney Dis</source> <volume>39</volume>: <fpage>930</fpage>–<lpage>936</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/ajkd.2002.32766" xlink:type="simple">10.1053/ajkd.2002.32766</ext-link></comment> <object-id pub-id-type="pmid">11979336</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rihal</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Textor</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Grill</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Berger</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Ting</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Best</surname> <given-names>PJ</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention</article-title>. <source>Circulation</source> <volume>105</volume>: <fpage>2259</fpage>–<lpage>2264</lpage>. <object-id pub-id-type="pmid">12010907</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gupta</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gurm</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Bhatt</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Chew</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Ellis</surname> <given-names>SG</given-names></name> (<year>2005</year>) <article-title>Renal failure after percutaneous coronary intervention is associated with high mortality</article-title>. <source>Catheter Cardiovasc Interv</source> <volume>64</volume>: <fpage>442</fpage>–<lpage>448</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ccd.20316" xlink:type="simple">10.1002/ccd.20316</ext-link></comment> <object-id pub-id-type="pmid">15789398</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liss</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Persson</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Hansell</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lagerqvist</surname> <given-names>B</given-names></name> (<year>2006</year>) <article-title>Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media</article-title>. <source>Kidney Int</source> <volume>70</volume>: <fpage>1811</fpage>–<lpage>1817</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.ki.5001887" xlink:type="simple">10.1038/sj.ki.5001887</ext-link></comment> <object-id pub-id-type="pmid">17003814</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartel</surname> <given-names>DP</given-names></name> (<year>2004</year>) <article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>. <source>Cell</source> <volume>116</volume>: <fpage>281</fpage>–<lpage>297</lpage>. <object-id pub-id-type="pmid">14744438</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tan</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>JX</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>X</given-names></name>. (<year>2016</year>) <article-title>Intraglomerular crosstalk elaborately regulates podocyte injury and repair in diabetic patients: insights from a 3D multiscale modeling study</article-title>. <source>Oncotarget</source> <volume>7</volume>: <fpage>73130</fpage>–<lpage>73146</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.12233" xlink:type="simple">10.18632/oncotarget.12233</ext-link></comment> <object-id pub-id-type="pmid">27683034</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McCullough</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Bertrand</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Brinker</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Stacul</surname> <given-names>F</given-names></name> (<year>2006</year>) <article-title>A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media</article-title>. <source>J Am Coll Cardiol</source> <volume>48</volume>: <fpage>692</fpage>–<lpage>699</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2006.02.073" xlink:type="simple">10.1016/j.jacc.2006.02.073</ext-link></comment> <object-id pub-id-type="pmid">16904536</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Middleton</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Foley</surname> <given-names>RN</given-names></name>, <name name-style="western"><surname>Hegarty</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>McElduff</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gibson</surname> <given-names>JM</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>The unrecognized prevalence of chronic kidney disease in diabetes</article-title>. <source>Nephrol Dial Transplant</source> <volume>21</volume>: <fpage>88</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ndt/gfi163" xlink:type="simple">10.1093/ndt/gfi163</ext-link></comment> <object-id pub-id-type="pmid">16221715</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bachorzewska-Gajewska</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Malyszko</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Malyszko</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Musial</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Dobrzycki</surname> <given-names>S</given-names></name> (<year>2006</year>) <article-title>Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention</article-title>. <source>Nephrology (Carlton)</source> <volume>11</volume>: <fpage>549</fpage>–<lpage>554</lpage>.</mixed-citation></ref>
<ref id="pone.0194330.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>New</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Middleton</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Klebe</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Farmer</surname> <given-names>CK</given-names></name>, <name name-style="western"><surname>de Lusignan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stevens</surname> <given-names>PE</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice</article-title>. <source>Diabet Med</source> <volume>24</volume>: <fpage>364</fpage>–<lpage>369</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1464-5491.2007.02075.x" xlink:type="simple">10.1111/j.1464-5491.2007.02075.x</ext-link></comment> <object-id pub-id-type="pmid">17335468</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hernandez</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mora</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Garcia-Tejada</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Velazquez</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gomez-Blazquez</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Bastante</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty</article-title>. <source>Rev Esp Cardiol</source> <volume>62</volume>: <fpage>1373</fpage>–<lpage>1380</lpage>. <object-id pub-id-type="pmid">20038403</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref016"><label>16</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JPT</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S</given-names></name>, <collab>Cochrane Collaboration</collab>. (<year>2008</year>) <chapter-title>Cochrane handbook for systematic reviews of interventions</chapter-title>. <publisher-loc>Chichester, England; Hoboken, NJ</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name>. <volume>xxi</volume>, 649 p. p.</mixed-citation></ref>
<ref id="pone.0194330.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aspelin</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Aubry</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fransson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Strasser</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Willenbrock</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Berg</surname> <given-names>KJ</given-names></name>. (<year>2003</year>) <article-title>Nephrotoxic effects in high-risk patients undergoing angiography</article-title>. <source>N Engl J Med</source> <volume>348</volume>: <fpage>491</fpage>–<lpage>499</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa021833" xlink:type="simple">10.1056/NEJMoa021833</ext-link></comment> <object-id pub-id-type="pmid">12571256</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Fu</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study</article-title>. <source>EuroIntervention</source> <volume>8</volume>: <fpage>830</fpage>–<lpage>838</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4244/EIJV8I7A126" xlink:type="simple">10.4244/EIJV8I7A126</ext-link></comment> <object-id pub-id-type="pmid">23045301</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hardiek</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Katholi</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Robbs</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Katholi</surname> <given-names>CE</given-names></name> (<year>2008</year>) <article-title>Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography</article-title>. <source>Journal of Diabetes and Its Complications</source> <volume>22</volume>: <fpage>171</fpage>–<lpage>177</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jdiacomp.2006.11.002" xlink:type="simple">10.1016/j.jdiacomp.2006.11.002</ext-link></comment> <object-id pub-id-type="pmid">18413220</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Solomon</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Natarajan</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Doucet</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Staniloae</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Katholi</surname> <given-names>RE</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease</article-title>. <source>Circulation</source> <volume>115</volume>: <fpage>3189</fpage>–<lpage>3196</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.106.671644" xlink:type="simple">10.1161/CIRCULATIONAHA.106.671644</ext-link></comment> <object-id pub-id-type="pmid">17562951</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shin</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Youn</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Yoon</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Suh</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>KI</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography</article-title>. <source>Am J Cardiol</source> <volume>108</volume>: <fpage>189</fpage>–<lpage>194</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2011.03.019" xlink:type="simple">10.1016/j.amjcard.2011.03.019</ext-link></comment> <object-id pub-id-type="pmid">21545991</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Laskey</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Aspelin</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rudnick</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aubry</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures</article-title>. <source>Am Heart J</source> <volume>158</volume>: <fpage>822</fpage>–<lpage>828</lpage> e823. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2009.08.016" xlink:type="simple">10.1016/j.ahj.2009.08.016</ext-link></comment> <object-id pub-id-type="pmid">19853704</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rudnick</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Laskey</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Stafford</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Sherwin</surname> <given-names>PF</given-names></name> (<year>2008</year>) <article-title>Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial</article-title>. <source>Am Heart J</source> <volume>156</volume>: <fpage>776</fpage>–<lpage>782</lpage>. <object-id pub-id-type="pmid">18946896</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jo</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Youn</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Koo</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>YS</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial</article-title>. <source>J Am Coll Cardiol</source> <volume>48</volume>: <fpage>924</fpage>–<lpage>930</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2006.06.047" xlink:type="simple">10.1016/j.jacc.2006.06.047</ext-link></comment> <object-id pub-id-type="pmid">16949481</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chuang</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>IK</given-names></name>, <name name-style="western"><surname>Chuang</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Ting-Yu Chiou</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Comparison of iodixanol and iohexol in patients undergoing intravenous pyelography: a prospective controlled study</article-title>. <source>Ren Fail</source> <volume>31</volume>: <fpage>181</fpage>–<lpage>188</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/08860220802669636" xlink:type="simple">10.1080/08860220802669636</ext-link></comment> <object-id pub-id-type="pmid">19288321</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feldkamp</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Baumgart</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Elsner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Herget-Rosenthal</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pietruck</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Erbel</surname> <given-names>R</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients</article-title>. <source>Clin Nephrol</source> <volume>66</volume>: <fpage>322</fpage>–<lpage>330</lpage>. <object-id pub-id-type="pmid">17140161</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuhn</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Sahani</surname> <given-names>DV</given-names></name>, <name name-style="western"><surname>Reimer</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>van Beek</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Heiken</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure</article-title>. <source>AJR Am J Roentgenol</source> <volume>191</volume>: <fpage>151</fpage>–<lpage>157</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2214/AJR.07.3370" xlink:type="simple">10.2214/AJR.07.3370</ext-link></comment> <object-id pub-id-type="pmid">18562739</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name> (<year>2009</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>BMJ</source> <volume>339</volume>: <fpage>b2535</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.b2535" xlink:type="simple">10.1136/bmj.b2535</ext-link></comment> <object-id pub-id-type="pmid">19622551</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lewis</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Burge</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Bartel</surname> <given-names>DP</given-names></name> (<year>2005</year>) <article-title>Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets</article-title>. <source>Cell</source> <volume>120</volume>: <fpage>15</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2004.12.035" xlink:type="simple">10.1016/j.cell.2004.12.035</ext-link></comment> <object-id pub-id-type="pmid">15652477</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bartholomew</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Harjai</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Dukkipati</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Boura</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Yerkey</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Glazier</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification</article-title>. <source>American Journal of Cardiology</source> <volume>93</volume>: <fpage>1515</fpage>–<lpage>1519</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2004.03.008" xlink:type="simple">10.1016/j.amjcard.2004.03.008</ext-link></comment> <object-id pub-id-type="pmid">15194023</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>DeVries</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Piper</surname> <given-names>WD</given-names></name>, <name name-style="western"><surname>Robb</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Hearne</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Ver Lee</surname> <given-names>PM</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Serious renal dysfunction after percutaneous coronary interventions can be predicted</article-title>. <source>American Heart Journal</source> <volume>155</volume>: <fpage>260</fpage>–<lpage>266</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2007.10.007" xlink:type="simple">10.1016/j.ahj.2007.10.007</ext-link></comment> <object-id pub-id-type="pmid">18215595</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mehran</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Aymong</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Nikolsky</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Lasic</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Iakovou</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Fahy</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention—Development and initial validation</article-title>. <source>Journal of the American College of Cardiology</source> <volume>44</volume>: <fpage>1393</fpage>–<lpage>1399</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2004.06.068" xlink:type="simple">10.1016/j.jacc.2004.06.068</ext-link></comment> <object-id pub-id-type="pmid">15464318</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rihal</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Textor</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Grill</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Berger</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Ting</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Best</surname> <given-names>PJ</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention</article-title>. <source>Circulation</source> <volume>105</volume>: <fpage>2259</fpage>–<lpage>2264</lpage>. <object-id pub-id-type="pmid">12010907</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dangas</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Iakovou</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Nikolsky</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Aymong</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Mintz</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Kipshidze</surname> <given-names>NN</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables</article-title>. <source>American Journal of Cardiology</source> <volume>95</volume>: <fpage>13</fpage>–<lpage>19</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2004.08.056" xlink:type="simple">10.1016/j.amjcard.2004.08.056</ext-link></comment> <object-id pub-id-type="pmid">15619387</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reed</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Meier</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tamhane</surname> <given-names>UU</given-names></name>, <name name-style="western"><surname>Welch</surname> <given-names>KB</given-names></name>, <name name-style="western"><surname>Moscucci</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gurm</surname> <given-names>HS</given-names></name>. (<year>2009</year>) <article-title>The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials</article-title>. <source>JACC Cardiovasc Interv</source> <volume>2</volume>: <fpage>645</fpage>–<lpage>654</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcin.2009.05.002" xlink:type="simple">10.1016/j.jcin.2009.05.002</ext-link></comment> <object-id pub-id-type="pmid">19628188</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heinrich</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Haberle</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Bautz</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Uder</surname> <given-names>M</given-names></name> (<year>2009</year>) <article-title>Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials</article-title>. <source>Radiology</source> <volume>250</volume>: <fpage>68</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1148/radiol.2501080833" xlink:type="simple">10.1148/radiol.2501080833</ext-link></comment> <object-id pub-id-type="pmid">19092091</object-id></mixed-citation></ref>
<ref id="pone.0194330.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>From</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Al Badarin</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>McDonald</surname> <given-names>FS</given-names></name>, <name name-style="western"><surname>Bartholmai</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Cha</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Rihal</surname> <given-names>CS</given-names></name>. (<year>2010</year>) <article-title>Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials</article-title>. <source>Circ Cardiovasc Interv</source> <volume>3</volume>: <fpage>351</fpage>–<lpage>358</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCINTERVENTIONS.109.917070" xlink:type="simple">10.1161/CIRCINTERVENTIONS.109.917070</ext-link></comment> <object-id pub-id-type="pmid">20647563</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>